Abstract:Abstract Head and neck squamous cell carcinoma (HNSCC) comprises 3% of all cancer cases worldwide. Despite intensive multimodal therapies, HNSCC patient outcomes remain heterogeneous with minimal improvements in survival. Utilization of fluid-based biomarkers for prognostication, risk stratification, and disease surveillance may improve patient outcomes by enabling more effective treatment decisions. Here, we describe the performance of comprehensive mutation and methylome analysis for highly sensitive detection of circulating tumor (ct)DNA in HNSCC plasma. To detect HNSCC-specific mutations and aberrant methylation in ctDNA, we conducted CAPP-Seq (CAncer Personalized Profiling by deep Sequencing) and cfMeDIP-seq (cell-free Methylated DNA ImmunoPrecipitation sequencing), respectively. For CAPP-Seq, we developed a HNSCC-specific hybrid capture panel and applied it to plasma DNA and peripheral blood leukocyte (PBL) genomic DNA from a cohort of HNSCC patients (n=32) and healthy controls (n=20). Single-nucleotide variants (SNVs) were identified by integrated digital error suppression (iDES). For cfMeDIP-seq, hypermethylated differentially methylated regions within regions of low PBL methylation were identified by DESeq2. A median of 3 mutations (range: 1-10) were detected by CAPP-Seq within plasma DNA of 20/32 (62.5%) HNSCC patients. Mean mutant allele frequency ranged from 0.1–5% (median: 0.92%) and correlated with tumor stage. Among these 20 patients, cfMeDIP-seq identified 860 DMRs that were enriched (hypermethylated) in HNSCC plasma DNA compared with healthy controls. These hypermethylated DMRs (hyper-DMRs) were over-represented by CpG islands and gene promoters and showed significant overlap with HNSCC-specific methylated regions in TCGA. When applied to all 32 HNSCC patients, hyper-DMR abundance was positively correlated with mutation-based ctDNA abundance (R=0.87; p=1e−16). Hyper-DMRs were capable of accurate discrimination of HNSCC patients and healthy controls (AUC=0.85). The median DNA fragment size within these hyperDMRs was lower in HNSCC patients compared to healthy controls—a characteristic of ctDNA described in previous studies—and correlated with both hyperDMR-based and mutation-based ctDNA abundance. We have conducted the first comparative analysis of genetic and epigenetic profiling approaches for ctDNA detection in HNSCC. Both CAPP-Seq and cfMeDIP-seq have the potential to detect ctDNA in patient plasma without prior knowledge of patient-specific tumor aberrations. With CAPP-seq, ctDNA was detectable at levels as low as 0.1%. Plasma methylome profiling using cfMeDIP-seq revealed hyper-DMRs with tumor-related features and that correlated with mutation-based ctDNA abundance. Future analysis will validate patient-specific mutations and methylation signals in tumor tissue and in longitudinally collected samples from this cohort. This abstract is also being presented as Poster B47. Citation Format: Justin M. Burgener, Jinfeng Zou, Zhen Zhao, Shu Y. Shen, Daniel D. De Carvalho, Scott V. Bratman. Comprehensive detection of ctDNA in localized head and neck cancer by genome- and methylome-based analysis [abstract]. In: Proceedings of the AACR Special Conference on Advances in Liquid Biopsies; Jan 13-16, 2020; Miami, FL. Philadelphia (PA): AACR; Clin Cancer Res 2020;26(11_Suppl):Abstract nr PR13.

Increased Plasma Dna Integrity Index in Head and Neck Cancer Patients

Quantitative analysis of free-circulating DNA in plasma of patients with resectable NSCLC

Abstract 2419: Personalized longitudinal ctDNA monitoring is useful for biomarker in head and neck squamous cell carcinoma

Increased integrity of circulating cell-free DNA in plasma of patients with acute leukemia.

A sensitive method for quantitative measurement of plasma dna: a marker for cancer progression and treatment

Droplet digital PCR for detection and quantification of circulating tumor DNA in plasma of head and neck cancer patients

Abstract P3-01-02: Quantitative Analysis and Diagnostic Significance of Methylated SLC19A3 DNA in the Plasma of Breast Cancer Patients

Plasma DNA Integrity As a Prognostic Biomarker for Colorectal Cancer Chemotherapy

Personalized circulating tumor DNA for monitoring disease status in head and neck squamous cell carcinoma

Cancer Stage-Dependent Alterations In Cell-Free Dna In Patients With Colorectal Caner

Quantitation of Plasma Circulating DNA Using Quantitative PCR for the Detection of Hepatocellular Carcinoma

Towards effectiveness of cell free DNA based liquid biopsy in head and neck squamous cell carcinoma

Tumor-Naïve Multimodal Profiling of Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma

Early circulating tumor DNA changes predict outcomes in head and neck cancer patients under re-radiotherapy

Individualized circulating tumor DNA monitoring in head and neck squamous cell carcinoma

Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nonnasopharyngeal head and neck carcinomas

Abstract PR13: Comprehensive Detection of Ctdna in Localized Head and Neck Cancer by Genome- and Methylome-Based Analysis

Quantification,integrity Evaluation and Clinical Significance of Circulating DNA in Plasma of Leukemia Patients

Circulating tumour DNA kinetics in recurrent/metastatic head and neck squamous cell cancer patients

Plasma Dna Methylation Analysis In Predicting Short-Term Recurrence Of Surgical Patients With Non-Small Cell Lung Cancer (Nsclc)

Circulating H3K27 Methylated Nucleosome Plasma Concentration: Synergistic Information with Circulating Tumor DNA Molecular Profiling